GlassScriptPhysician profile
Hsiao-Hui Lin
NPI 1548254246
$3,535.23
in general payments reported to CMS, 2019-2025
31 companies · $24.41 in 2025
The $24.41 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $606 · 2021: $684 · 2022: $794 · 2023: $820 · 2025: $24.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.87 |
| Education | $127.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.70 | 2019-2023 | |
| Pfizer INC. | $405.07 | 2019-2023 | |
| Therapeuticsmd, INC. | $357.72 | 2019-2022 | |
| Exeltis, USA INC. | $276.25 | 2019-2023 | Slynd |
| Avion Pharmaceuticals | $214.75 | 2019-2023 | Balcoltra |
| Astellas Pharma US INC | $204.20 | 2023 | Veozah |
| Millicent US INC | $133.86 | 2019-2023 | Femring, Intrarosa |
| Myovant Sciences INC. | $116.23 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.44 | 2019-2021 | |
| Allergan, INC. | $74.04 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $70.77 | 2019 | |
| Mayne Pharma Commercial LLC | $69.91 | 2022-2023 | |
| Evofem Biosciences, INC. | $67.13 | 2021-2023 | Phexxi |
| Biohaven Pharmaceutical Holding Company LTD. | $54.66 | 2022 | |
| Scynexis, INC. | $52.86 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $43.23 | 2020-2021 | |
| Duchesnay USA Incorporated | $39.09 | 2019 | |
| Agile Therapeutics, INC. | $38.36 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $37.15 | 2021 | |
| Amgen INC. | $36.62 | 2023-2025 | Evenity, Prolia |
| Organon LLC | $33.28 | 2022-2025 | Vtama |
| Hologic Sales and Service, LLC | $21.24 | 2021 | |
| Coopersurgical, INC. | $19.57 | 2019 | |
| Shield Therapeutics INC | $17.03 | 2023 | Accrufer |
| Applied Medical Resources Corporation | $16.32 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $14.51 | 2022 | |
| Lupin INC. | $14.33 | 2019 | |
| Minerva Surgical, INC | $14.13 | 2022 | |
| Mission Pharmacal Company | $13.83 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.95 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hsiao-Hui Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.